HDFC Life Insurance Company has completed the allotment of 1,45,23,906 fully paid-up equity shares to its promoter HDFC Bank on June 16, 2026. The shares were issued at a price of ₹688.52 per equity share, with a face value of ₹10 each. As per the official exchange filing, the company confirmed that all relevant regulatory approvals and shareholder approvals were obtained prior to the allotment, with shareholders approving the proposal through a special resolution passed via postal ballot on May 16, 2026. The Board of Directors approved the allotment following the receipt of necessary regulatory clearances, with the filing signed by Nagesh Pai, Company Secretary and Compliance Officer of HDFC Life Insurance Company Limited.
Following this allotment, the paid-up equity share capital of HDFC Life Insurance Company now stands at ₹21,72,47,49,810, comprising 2,17,24,74,981 equity shares of face value ₹10 each. The transaction represents a promoter-led capital infusion rather than a public fundraising exercise, with the preferential allotment structure ensuring the transaction remains within the promoter group. As reported in the official filing, this capital infusion strengthens the promoter's stake in the company and reflects continued support from HDFC Bank toward HDFC Life's long-term growth plans. The company informed stock exchanges that the development is being disclosed for information and wider dissemination.
The share allotment was executed on a preferential basis to HDFC Bank, which serves as the promoter of HDFC Life Insurance Company. This preferential allotment structure allows the company to issue shares directly to existing promoters without going through public market channels, ensuring the transaction remains within the promoter group. The transaction is largely capital-structure related and does not introduce significant operational risks, though future returns on the additional capital deployed will depend on business growth, profitability, and insurance market conditions. The filing was submitted to both NSE and BSE on Tuesday, following earlier disclosures made by the insurer on April 16 and April 23, 2026, regarding the proposed capital infusion.
